Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Administration of LMP1- and LMP2-Specific Cytotoxic T-Lymphocytes Following CD45 Antibody Administration to Patients With EBV-Positive Nasopharyngeal Carcinoma

NCT00515957 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT00515957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00515957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Administration of LMP1- and LMP2-Specific Cytotoxic T-Lymphocytes Following CD45 Antibody Administration to Patients With EBV-Positive Nasopharyngeal Carcinoma
Lead sponsor
Baylor College of Medicine
Phase
Phase 1
Overall status
Withdrawn
Start date
August 31, 2007
Completion date
August 31, 2010
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal carcinoma